Who is sponsoring NCT02266914?

NCT02266914 is sponsored by Ohio State University.

What drugs are being tested in NCT02266914?

Interventions in NCT02266914: Magnetic Resonance Elastography driver.

What condition does NCT02266914 study?

NCT02266914 studies Acute Graft Rejection.

Is NCT02266914 still recruiting?

NCT02266914 is currently terminated. Last updated 22 May 2019.

Are results published for NCT02266914?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2019-05-22 · How we verify

NCT02266914

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Magnetic Resonance Elastography of Cardiac Transplant Rejection

Terminated NA Results posted Last updated 22 May 2019

What this trial tests

NA trial testing Magnetic Resonance Elastography driver in Acute Graft Rejection in 9 participants. Terminated before completion.

Timeline

27 January 2014

Primary endpoint
1 December 2017

1 December 2017

Quick facts

Lead sponsor	Ohio State University
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	9
Start date	27 January 2014
Primary completion	1 December 2017
Estimated completion	1 December 2017
Sites	1 location across United States

Drugs / interventions tested

Magnetic Resonance Elastography driver

Conditions studied

Acute Graft Rejection — all drugs for Acute Graft Rejection →

Sponsor

Ohio State University

Who can join

18 and older, any sex, with Acute Graft Rejection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Magnetic Resonance Elastography (MRE) for cardiac transplant patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Acute Graft Rejection

Currently open trials in the same condition.

NCT06557564 — Diagnosis of Graft Pathology by TruGraf · recruiting

Other Ohio State University trials

Trials by the same sponsor.

NCT06542458 — Under-Represented Communities Diagnosed With SCD or MCI Through Tele-Cog · not yet recruiting
NCT07217548 — Solving Stigma Through POV Simulation: Enhancing Pharmacist Empathy-based Practices With Sickle Cell Disease Patients · NA · enrolling by invitation
NCT07215221 — Implementation of TBI-RECOVER in Substance Use Treatment · NA · not yet recruiting
NCT07278427 — Reducing Parental Substance Use and Enhancing Family Resilience Among Rural Families Through Ohio START · recruiting
NCT07490444 — Metric-Optimized Spectacle Prescriptions for Children With Down Syndrome · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02266914 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ohio State University
Last refreshed: 22 May 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02266914.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing